软组织肉瘤分子靶向治疗研究进展

Advances in molecular targeted therapy for soft tissue sarcomas

软组织肉瘤(soft tissue sarcoma,STS)是一组起源于间叶组织的恶性肿瘤,约占成人恶性肿瘤的1%,恶性程度较高和亚类繁多是其主要特点。目前主要治疗手段包括手术、放疗及化疗等。与胃肠间质瘤对伊马替尼的良好反应不同,其他STS的治疗面临着更多困难,不同亚型间遗传性和临床特点异质性强,生存时间差异较大。近年来,分子靶向药物的应用进展迅速,在个体化治疗和提高患者生存质量等方面优势明显,为不宜手术和不能接受常规化疗的患者提供了新的治疗手段。本文就近年来STS的靶向治疗药物和相关通路进行简要阐述。

Sarcomas are tumors of mesenchymal origin that account for approximately 1% of human cancers. There are at least 60 dif- ferent subtypes of soft tissue sarcoma （STS）. However, most tumor types are highly malignant tumors that lack an optimal therapeutic agent. Although gastrointestinal stromal tumor （GIST） responds well to imatinib, other types of STSs remain challenging because of their heterogeneous genetic and clinical features and poor prognosis. In recent years, the field of molecular targeted therapy has pro- gressed rapidly. Patients with advanced disease can receive individualized treatment to improve their quality of life. This review focus- es on the targeted therapies that have been evaluated for advanced non-GIST STS. Other promising novel therapeutic agents that are currently in the early phases of investigation are also presented.